Ann Coloproctol.  2022 Apr;38(2):97-108. 10.3393/ac.2021.01004.0143.

Pretreatment inflammatory markers predicting treatment outcomes in colorectal cancer

• An S
• Shim H
• Kim K
• Kim B
• Bang HJ
• Do H
• Lee HR
• Kim Y

• KMID: 2528179
• DOI: http://doi.org/10.3393/ac.2021.01004.0143

Abstract

We aimed to review whether pretreatment inflammatory markers reflect the short- and long-term outcomes of patients with colon cancer, rectal cancer, colon and rectal cancers, and metastatic colorectal cancer (CRC). We found that pretreatment complete blood count and blood chemistry tests reflect short-term and long-term oncological outcomes in patients with CRC. Specifically, in patients with colon cancer, hypoalbuminemia was associated with worse postoperative morbidity, mortality, and inferior survival. In patients with rectal cancer, elevated neutrophil-lymphocyte ratio (NLR) and thrombocytosis were associated with postoperative complications, poor overall survival (OS), and disease-free survival (DFS). A high C-reactive protein/albumin ratio (CAR) was associated with poor OS and DFS. In patients with metastatic CRC, increased NLR and platelet-lymphocyte ratio (PLR) were associated with poor OS, DFS, and progression-free survival (PFS). In addition, high CAR and a low albumin/globulin ratio on blood chemistry tests were associated with poor OS and PFS. Although universal cut-off values were not available, various types of pretreatment laboratory markers could be utilized as adjuncts to predict prognosis in patients with CRC.

Keyword

Colonic neoplasms; Rectal neoplasms; Inflammation; Biomarkers; Prognosis